Search Results (1,514)

Metabolic associated fatty liver disease (MAFLD), redefined from non-alcoholic fatty liver disease (NAFLD), is a global health concern driving the search for dietary interventions based on natural compounds. Phloroglucinaldehyde (PGA), a primary phenolic metabolite of the widely consumed anthocyanin cyanidin-3-glucoside (C3G) found in berries and other fruits, has emerged as a promising candidate due to its potential higher bioavailability than its parent compound. This study investigates the protective effects of PGA against high-fat diet (HFD)-induced MAFLD. Using both in vitro (LO2 cells) and in vivo (C57BL/6J mice) models, we found that PGA administration significantly attenuated body weight gain and hepatic steatosis, while reducing serum levels of TG, TC, liver transaminases (AST & ALT), and insulin resistance (p < 0.05). Further liver lipidomic profiling revealed that PGA supplementation specifically down-regulated 46 lipid species (p < 0.05), predominantly triglycerides characterized by long-chain and very-long-chain saturated fatty acids. Mechanistically, PGA enhanced the hepatic antioxidant capacity by increasing superoxide dismutase (SOD) activity (p < 0.05) and decreasing malondialdehyde (MDA) (p < 0.05) and exerted anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, TNF, MCP-1) (p < 0.05) and endotoxin levels (p < 0.05). Correlation analyses further linked the down-regulated lipids to improvements in oxidative stress and inflammation. Our findings underscore that PGA, a key bioactive metabolite derived from dietary anthocyanins, alleviates MAFLD through its potent antioxidant and anti-inflammatory properties, highlighting its potential as a functional food ingredient or nutraceutical for metabolic health. Full article

Background: Altered lipid metabolism has been reported in several malignancies, but its clinical relevance in non-small cell lung cancer (NSCLC) remains uncertain. This study aimed to compare serum lipid parameters between NSCLC patients and healthy controls and to explore their association with histological subtype and selected driver mutations. Methods: We retrospectively analyzed serum total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), and triglycerides (TG) in patients diagnosed with adenocarcinoma or squamous cell carcinoma from 2021 to 2024, alongside a control group of 100 healthy individuals. Statistical comparisons were performed using appropriate parametric or nonparametric tests after normality assessment (Shapiro–Wilk), and p-values were adjusted using the Benjamini–Hochberg false discovery rate (FDR). Results: A total of 160 NSCLC patients were included. Most were male (75.5%) and current or former smokers (96.1%), with a mean age of 70.4 ± 10.3 years. Squamous cell carcinoma was the predominant subtype (64.4%). Hypocholesterolemia was observed in 59.9% of patients, while hypercholesterolemia was less frequent (40.1%). Compared with controls, patients had significantly lower HDL levels (p = 0.007, FDR-adjusted p = 0.024), while other lipid markers showed no statistically significant differences after correction for multiple testing. Differences between adenocarcinoma and squamous cell carcinoma were not statistically significant. Squamous cell carcinoma patients had higher TG but lower TC, LDL, and HDL levels compared with adenocarcinoma. A negative correlation between TG and ROS1 expression remained significant (r = −0.223, FDR-adjusted p = 0.004). Conclusions: In this retrospective, real-world cohort, only HDL levels demonstrated a robust difference between NSCLC patients and controls. Observed associations should be interpreted cautiously due to potential confounding factors and incomplete clinical data inherent to retrospective analyses. Prospective studies are needed to clarify whether lipid alterations play a biological or prognostic role in NSCLC. Full article

To explore a safe and effective approach for producing strontium-enriched fish, in this study, we modified the feed for juvenile hybrid sturgeon (Acipenser baerii ♀ × Acipenser schrenckii ♂) and set three different levels of strontium chloride content in their diet (0 mg/kg (Sr0, control), 80 mg/kg (Sr80), and 160 mg/kg (Sr160)) for a period of 8 weeks, analyzing their growth performance, strontium enrichment, muscle nutrition, and hepatic physiological, biochemical, and transcriptomic characteristics. The results show that dietary strontium had no significant impact on sturgeon growth or survival rate (p > 0.05). The strontium content in tissues increased with dietary strontium levels, with the highest enrichment in bone plates (p < 0.05). However, muscle crude fat in the strontium-supplemented groups decreased significantly; the Sr160 group had higher glutamic acid, valine, docosahexaenoic acid methyl ester, lower myristic acid, palmitic acid, etc. (p < 0.05). In addition, strontium treatment alleviated hepatic lipid accumulation and mitochondrial swelling. Biochemical analyses revealed reduced plasma levels of Triglyceride (TG), Total Cholesterol (TC), Alanine Aminotransferase (ALT), and Aspartate Aminotransferase (AST), as well as decreased hepatic Malondialdehyde (MDA) content, while hepatic Glutathione (GSH) levels increased (p < 0.05). Transcriptomic data further showed that strontium downregulated the expression of fasn and tfrc and upregulated the expression of cpt1a, apoa1, cyp7a1, and slc3a2 (p < 0.05). In conclusion, dietary supplementation with 80–160 mg/kg strontium enables safe strontium enrichment in hybrid sturgeon, improves muscle nutritional quality, and protects liver function by regulating the genes related to lipid metabolism and antioxidant defense, providing a scientific basis for the development of strontium-enriched fish products. Full article

Objective: This randomized, double-blind, placebo-controlled clinical trial assessed the efficacy and safety of steamed ginger extract (GGE03), standardized to high levels of 1-dehydro-6-gingerdione (GD), in reducing body fat and weight among overweight individuals. Methods: Eighty adults aged 18 to 60 years, with a body mass index (BMI) of 25.0 to 29.9 kg/m², were randomly assigned to receive either GGE03 (n = 40; 480 mg/day) or a placebo (n = 40) for 12 weeks. Efficacy and safety parameters were evaluated at baseline and after the intervention period. Results: After 12 weeks, the GGE03 group showed statistically significant reductions in body fat percentage and body fat mass compared to the placebo group, as measured by dual-energy X-ray absorptiometry (DEXA). Additionally, significant decreases in body weight, BMI, waist circumference, and hip circumference were observed following GGE03 supplementation. Serum triglyceride (TG) and total cholesterol (TC) levels were also significantly lower in the GGE03 group compared to the placebo group. No product-related adverse events or clinically significant laboratory abnormalities were noted, indicating that GGE03 was well tolerated. Conclusions: Twelve weeks of GGE03 supplementation were associated with statistically significant improvements in body composition and lipid parameters without safety concerns. These findings support the potential of GD-standardized GGE03 as a well-tolerated functional dietary ingredient for body fat management and metabolic health. Full article

The quality of high-density lipoproteins (HDLs) is characterized by lipid and protein composition, oxidation and glycation extent, and particle size, while the quantity of HDL-C is just the cholesterol amount in HDL. The inverse association between HDL-C and cardiovascular disease (CVD) and hypertension has been well established; however, the U-shaped mortality risk observed from HDL-C underscores that HDL quality and function are equally important. The present cross-sectional study assessed the correlations of serum lipid and glucose profiles, and low-density lipoprotein (LDL) and HDL characteristics, with blood pressure (BP) distribution in ordinary middle-aged Korean participants (n = 50; mean age 47.0 ± 11.7 years; males: n = 25, 49.2.0 ± 11.7 years; females: n = 25, 44.8 ± 11.5 years), with particular focus on HDL quality and its antioxidant capacity. This study observed that serum elevated triglyceride (TG) and glucose levels were directly proportional to elevated systolic BP (SBP) and diastolic BP (DBP), whereas serum total cholesterol (TC), LDL-C, and HDL-C were not correlated with BP. However, HDL-C/TC (%) was negatively associated with SBP (p = 0.036), while TG/HDL-C and glucose/HDL-C ratios were positively associated with both SBP and DBP, suggesting that TG and glucose proportions relative to HDL-C are probable predictors of hypertension. Elevations of TG, oxidation, and glycation in LDL were positively associated with elevations of BP, whereas LDL particle size was negatively correlated with BP. Similarly, elevations of TG and glycation in HDL₂ and HDL₃ were positively correlated with elevations of BP, while the particle size of HDL₂ was negatively correlated with BP. The heightened HDL₂-associated paraoxonase (PON) activity and ferric ion reduction ability (FRA) negatively correlated with LDL oxidation and particle size, whereas elevated HDL₃-associated PON and FRA activities were inversely related to LDL glycation. An enhanced glycation in HDL₂ was negatively correlated with HDL₂-associated PON activity and FRA, while an increase in HDL₂ particle size was only dependent on the associated PON activity but not on FRA. In conclusion, observational outcomes demonstrated that improved HDL quality and functionality (characterized by large particle size, reduced glycation, and higher FRA and PON activities) were inversely correlated with LDL oxidation, glycation, particle shrinkage, and the risk of hypertension. Full article

Background/Objectives: Branched-chain fatty acids (BCFAs) exhibit a range of biological activities; however, their limited natural abundance and high cost have constrained in vivo research. Lanolin represents a promising source for enriching BCFAs. Nevertheless, the in vivo application, safety, and dose-effect relationship of BCFAs derived from lanolin (BCFAs-DFL) remain unassessed. Methods: In this study, the acute toxicity in C57BL/6J mice was first evaluated for 7 days by a single oral administration of 5000 mg/kg BW of BCFAs-DFL. Subsequently, 40 mice were divided into four groups (control group, low dose of 100 mg/kg BW, medium dose of 300 mg/kg BW, and high dose of 600 mg/kg BW) and were continuously administered by gavage for 28 days to study the effects of BCFAs-DFL on the growth, blood biochemistry, intestinal morphology, and intestinal flora of the mice. Results: In the acute toxicity test, BCFAs-DFL exhibited no lethality or abnormalities in mice, indicating its non-toxic nature. Throughout the 28-day trial, mice in the medium- and high-dose groups experienced a notable decrease in average daily feed intake (p < 0.05), yet their weight gain remained unaffected (p > 0.05). Hemoglobin and hematocrit levels declined in the high-dose group (p < 0.05). Conversely, serum aspartate aminotransferase and total bilirubin levels escalated in the medium- and high-dose groups, while triglycerides and urea nitrogen levels decreased (p < 0.05). The serum’s total antioxidant capacity and immunoglobulin levels (IgA, IgG) rose in proportion to the dosage (p < 0.05). BCFAs-DFL notably enhanced the villus height of the jejunum and ileum in mice (p < 0.05). Gut microbiota analysis indicated no significant impact on overall α and β diversity. Conclusions: The 28-day intervention revealed that BCFAs-DFL can modulate feeding behavior, TG, T-AOC, and immunoglobulin levels in mice. Additionally, it promotes the development of intestinal villi. Based on various indicators, a dosage of 100 mg/kg BW effectively induces beneficial metabolic regulation, such as the reduction of triglycerides, without causing a burden on liver metabolism. This dosage may represent a more suitable application for potential use. Full article

Background/Objectives: The triglyceride-to-High-density lipoprotein cholesterol (TG/HDL) ratio is an established marker of atherogenic dyslipidaemia and insulin resistance. Although its association with subclinical atherosclerosis has been reported, the relative contributions of long-term TG/HDL burden and visit-to-visit variability to carotid intima media thickness (CIMT) remain unclear. This study aimed to evaluate the differential associations of the longitudinal mean and temporal variability of the TG/HDL ratio with CIMT. Methods: This retrospective single-center observational cohort study included 260 adult patients with at least three years of longitudinal lipid measurements and a standardized carotid ultrasonography assessment. The longitudinal mean TG/HDL ratio and variability indices, including standard deviation, coefficient of variation, average real variability and variability independent of the mean, were calculated. CIMT was measured using B-mode ultrasonography. Associations were assessed using correlation analyses, multivariable linear regression, joint category analyses and stratified analyses according to statin therapy. Results: The longitudinal mean TG/HDL ratio was independently associated with increased CIMT after adjustment for traditional cardiovascular risk factors. In contrast, TG/HDL variability indices showed no independent association with CIMT and did not improve model performance beyond the mean TG/HDL ratio. Restricted cubic spline analysis demonstrated a significant non-linear association between TG/HDL mean and CIMT, suggesting a threshold-dependent relationship. Joint category analyses demonstrated higher CIMT values in groups with elevated TG/HDL mean regardless of variability status. A significant interaction was observed between TG/HDL variability and statin therapy (p for interaction = 0.011). Conclusions: These findings indicate that cumulative exposure to atherogenic dyslipidaemia, reflected by the long-term mean TG/HDL ratio, is more strongly associated with subclinical carotid atherosclerosis than short-term lipid fluctuations. Full article

Background and Objectives: Coronary artery disease (CAD) is a leading cause of morbidity and mortality worldwide. An early and accurate diagnosis is essential for effective clinical management and risk stratification. Recent advances in machine learning (ML) have provided opportunities to enhance the diagnostic performance by integrating multidimensional patient data. This study aimed to develop and compare several supervised ML algorithms for early CAD diagnosis using demographic, anthropometric, biochemical, and psychosocial parameters. Materials and Methods: A total of 300 adult patients (165 CAD-positive and 135 controls) were retrospectively analyzed using a dataset comprising 21 biochemical markers, body composition metrics, and self-reported eating behavior scores. Six ML algorithms, k-nearest neighbors (k-NNs), support vector machines (SVMs), artificial neural networks (ANNs), logistic regression (LR), naïve Bayes (NB), and decision trees (DTs), were trained and evaluated using 10-fold cross-validation. Model performance was assessed based on accuracy, sensitivity, false-negative rate, and area under the Receiver Operating Characteristic (ROC) curve (AUC). Results: The k-NN model achieved the highest performance, with 98.33% accuracy and an AUC of 0.99, followed by SVM (96.67%, AUC = 0.95) and ANN (95.33%, AUC = 0.98). Patients with CAD exhibited significantly higher levels of glucose, triglycerides (TGs), LDL cholesterol (LDL-C), and abdominal obesity, while vitamin B12 levels were lower (p < 0.001). Although emotional and mindful eating scores differed significantly between the groups, their contribution to model performance was limited. Conclusions: Machine learning models, particularly k-NN, SVM, and ANN, have demonstrated high accuracy in distinguishing CAD patients from healthy controls when applied to a diverse set of clinical and behavioral variables. This study highlights the potential of integrating psychosocial and clinical data to enhance CAD prediction models beyond traditional biomarkers. Full article

Background/Objectives: Type 2 diabetes (T2D) is a chronic metabolic disorder closely linked to cardiovascular disease and obesity and notably influenced by lifestyle and dietary patterns. The Mediterranean diet has well-established benefits across multiple cardiometabolic risk factors, including those relevant to diabetes. This study aimed to investigate the degree to which adults with T2D adhere to a Mediterranean dietary pattern and to examine how such adherence relates to glycemic and lipidemic regulation. Methods: This cross-sectional study included 100 adults with T2D (54 men and 46 women). Adherence to the Mediterranean diet was assessed using the Mediterranean Diet Score (MDS). Demographic, anthropometric, lifestyle, and clinical data were collected, and glycemic and lipid parameters were analyzed. Associations between Mediterranean diet adherence and metabolic outcomes were examined using correlation analyses and multivariable regression models adjusted for relevant confounders. Results: Most participants showed low adherence to the Mediterranean diet. A significant inverse association was observed between Mediterranean diet adherence and hemoglobin A1c (HbA1c) levels, with individuals scoring ≤35 on the MDS demonstrating higher HbA1c levels. Similar trends were observed in the lowest tertile of adherence. Notably, each one-point increase in MDS predicted a 0.13% reduction in HbA1c. In multivariable regression analyses, Mediterranean diet adherence remained the strongest predictor of glycemic control, independent of age, body mass index (BMI), sex, smoking status, physical activity and the number of antidiabetic treatments. Higher adherence was also significantly associated with lower low-density lipoprotein cholesterol (LDL-C) and triglyceride (TG) levels, as well as higher high-density lipoprotein cholesterol (HDL) concentrations. Conclusions: Greater adherence to the Mediterranean diet is independently associated with improved glycemic regulation and a more favorable lipid profile in adults with T2D. These findings support the Mediterranean diet as a valuable non-pharmacologic strategy for optimizing metabolic outcomes in people with T2D. Full article

Multiple sclerosis (MS) is traditionally recognized as a chronic immune-mediated disorder of the central nervous system (CNS), but increasing evidence suggests that systemic metabolic alterations may also contribute to its pathophysiology. Lipid abnormalities in MS have recently attracted renewed research interest, with studies focusing both on dysregulation of lipid signaling pathways and on alterations in standard lipid profile components, including total cholesterol (TC), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides (TG), and non-HDL cholesterol. Although disturbances in serum lipid profiles are consistently reported in patients with MS, their origin remains unresolved. Emerging data indicate that dyslipidemia may stem from aberrant cholesterol metabolism within the CNS, secondary to demyelination and myelin sheath destruction, leading to the release of lipid-rich debris and subsequent systemic metabolic imbalance. These lipid changes appear to correlate with blood–brain barrier (BBB) dysfunction, suggesting a link between peripheral lipid metabolism and CNS inflammation. This review summarizes current knowledge on the mechanisms underlying dyslipidemia in MS, its potential impact on disease progression, and its relevance as a possible therapeutic or biomarker target in future translational studies. Full article

Circulating irisin, a myokine implicated in energy expenditure and adipose tissue regulation, has been increasingly studied as a potential biomarker of metabolic dysfunction. This study evaluated the relationship between serum irisin and metabolic indices, including the atherogenic index of plasma (AIP), the lipid accumulation product (LAP), and hypertriglyceridemic-waist (HTGW) phenotype in individuals with prediabetes (PreDM) and newly diagnosed type 2 diabetes mellitus (T2DM). A total of 138 participants (48 PreDM, 90 T2DM) were assessed for anthropometric, glycemic, and lipid parameters. Serum irisin levels were measured by enzyme-linked immunosorbent assay (ELISA) and correlated with insulin resistance indices (Homeostatic Model Assessment of Insulin Resistance (HOMA-IR), Quantitative Insulin Sensitivity Check Index (QUICKI)), glycemic control (glycosylated hemoglobin A1c (HbA1c)), and composite lipid markers (total triglycerides-to-high-density lipoprotein cholesterol (TG/HDL-C)). Group differences were evaluated using non-parametric tests; two-way ANOVA assessed interactions between phenotypes and markers; multiple linear regression (MLR) and logistic regression models explored independent associations with metabolic indices and HTGW; receiver operating characteristic (ROC) analyses compared global and stratified model performance. Serum irisin was significantly lower in T2DM than in PreDM (median 140.4 vs. 230.7 ng/mL, p < 0.0001). Irisin levels remained comparable between males and females in both groups. Post hoc analysis shows that lipid indices and irisin primarily distinguish HTGW phenotypes, especially in T2DM. In both groups, irisin correlated inversely with HOMA-IR, AIP, and TG/HDL-C, and positively with QUICKI, indicating a possible compensatory role in early insulin resistance. MLR analyses revealed no independent relationship between irisin and either AIP or LAP in PreDM, while in T2DM, waist circumference remained the strongest negative predictor of irisin. Logistic regression identified age, male sex, and HbA1c as independent predictors of the HTGW phenotype, while irisin contributed modestly to overall model discrimination. ROC curves demonstrated good discriminative performance (AUC = 0.806 for global; 0.794 for PreDM; 0.813 for T2DM), suggesting comparable predictive accuracy across glycemic stages. In conclusion, irisin levels decline from prediabetes to overt diabetes and are inversely linked to lipid accumulation and insulin resistance but do not independently predict the HTGW phenotype. These findings support irisin’s role as an integrative indicator of metabolic stress rather than a stand-alone biomarker. Incorporating irisin into multi-parameter metabolic panels may enhance early detection of cardiometabolic risk in dysglycemic populations. Full article

Marine by-products represent an important source of bioactive lipids with potential applications in nutraceuticals and functional foods. This study provides a biochemical and lipidomic characterization of oils derived from sardine, monkfish, grey mullet roe, squid, and anchovy by-products, assessing how the extraction method influences their lipid and antioxidant profiles. Fatty acids were quantified by GC-FID, antioxidant compounds by HPLC-DAD, and untargeted lipidomics by TIMS-HRMS. A total of 228 lipid species were identified, predominantly triglycerides (TGs) and diglycerides (DGs), accounting for approximately 69% of the annotated lipidome. Grey mullet roe oils exhibited the highest levels of long-chain PUFAs (EPA, DHA) and antioxidants (α-tocopherol 205–469 mg/Kg, lutein 10–125 mg/Kg, and squalene 1004–6049 mg/Kg), whereas squid oils showed high n-3/n-6 proportions. The extraction method strongly affected lipid integrity. Supercritical CO₂ extraction with ethanol (SFE–SE) preserved the greatest proportion of PUFA-rich TGs, yielding ~27–28 g EPA + DHA per 100 g oil, while wet reduction and mechanical pressing produced lower PUFA levels (~22 g/100 g) and increased hydrolysis/oxidation-associated lipids. PCA and PLS-DA revealed clear clustering driven by species and extraction class, with PUFA-containing TGs and DGs identified as major discriminating lipids. These results highlight the critical role of extraction conditions in determining the nutritional and functional value of marine oils and support the valorization of marine by-products in high-value applications. Full article

This study investigated the effects of amylose/amylopectin (AM/AP) ratios in low-protein (LP) diets on the growth performance, fat deposition, and nutrient utilization in goslings. A total of 288 healthy, 35-day-old male Jiangnan White Geese were randomly divided into four treatment groups: one group fed a normal protein diet (16%) with an AM/AP ratio of 0.34 (NPR_0.34), and three groups fed low protein diets (14%) with different AM/AP ratios (LPR_0.26, LPR_0.34, LPR_0.44). Each group consisted of six replicates, with 12 geese per replicate, and they were fed for 28 days. The results showed that the body weight at 63 days and average daily gain (ADG) of the LPR_0.44 group geese were significantly higher than those of the other groups (p < 0.01), while the feed-to-gain ratio (F/G) was lower (p < 0.05). The abdominal and mesenteric fat contents were lower in the LPR_0.44 group than in the LPR_0.26 group (p < 0.05), whereas the breast and leg muscle yields were higher (p < 0.05). The breast muscle redness (a*) of the LPR_0.34 and LPR_0.44 groups was higher than in the NPR_0.34 group at 45 min (p < 0.05). The levels of C6:0, C8:0, C11:0, C12:0, and C13:0 in breast muscle saturated fatty acids (SFAs) of the LPR_0.44 group were higher, while that of C18:0 was lower compared with the LPR_0.26 group (p < 0.05). The serum total cholesterol (TC) and triglycerides (TGs) in the LPR_0.44 group were lower than in the LPR_0.26 group (p < 0.05). Hepatic lipase (HL) activity was significantly lower in the LPR_0.44 group (p < 0.01). Regarding hepatic fatty acids, the levels of butyric acid (C4:0), lauric acid (C12:0), and nervonic acid (C24:1) were lower in the LPR_0.44 group than in the LPR_0.26 group (p < 0.05). No significant differences were observed in intestinal morphology, digestive enzyme activities, or nutrient utilization among the groups. (p > 0.05). In conclusion, adjusting the AM/AP ratio to 0.44 in a low-protein diet improved growth performance, regulated lipid metabolism, and maintained intestinal function in goslings. Full article

Six new diterpenoids, including two verticillane ghardaqenoids A–B (1–2) and four dolabellane ghardaqenoids C–F (3–6), were isolated from the soft coral Heteroxenia ghardaqensis collected in the South China Sea. The structures of ghardaqenoids A, D, and E (1, 4, 5) were determined by X-ray diffraction. Ghardaqenoids B, C, and F (2, 3, 6) were identified on the basis of NMR data, DP4+, and ECD spectral data. In particular, compound 6 exhibited strong in vitro lipid-lowering activity in free fatty acid (FFA)-induced HepG2 cells and liver organoids. Further mechanistic studies revealed that compound 6 regulated AMPK-related proteins and genes, thereby inhibiting the accumulation of triglycerides (TG) and total cholesterol (TC). These findings suggested that pharmacological AMPK activation serves as a promising role in lipid-lowering therapeutic strategies. Full article

Background/Objectives: Metabolic syndrome (MetS) is a group of cardiometabolic risk factors whose current management relies on lifestyle changes and pharmacological interventions, frequently involving multiple medications. Therefore, the demand for therapies capable of delivering comprehensive management of MetS is increasing. In this context, nutraceuticals such as celery seed have attracted increasing scientific interest. This study aimed to evaluate the effect of celery seed (Apium graveolens L.) administration on the components of MetS, insulin sensitivity, and insulin secretion. Methods: A randomized, double-blind, placebo-controlled clinical trial was carried out in 28 patients with MetS. Fourteen patients randomly received celery seed (150 mg/day) for 12 weeks, and 14 subjects received a placebo. Clinical and laboratory determinations were evaluated at baseline and the end of the study. Results: After celery seed administration, patients showed a significant decrease in their systolic blood pressure (SBP) (121.0 ± 9.7 mmHg vs. 115.7 ± 12.8 mmHg, p = 0.005), diastolic blood pressure (DBP) (82.2 ± 5.9 mmHg vs. 78.5 ± 8.6 mmHg, p = 0.013), triglycerides (TG) (2.3 ± 0.9 mmol/L vs. 1.8 ± 0.6 mmol/L, p = 0.016), very low-density lipoprotein (VLDL) (0.4 ± 0.1 mmol/L vs. 0.3 ± 0.1 mmol/L, p = 0.016) and uric acid (297.4 ± 53.5 µmol/L vs. 261.7 ± 53.5 µmol/L, p = 0.009). Insulin sensitivity and insulin secretion showed no statistically significant differences in the celery seed group. Conclusions: Celery seed administration significantly reduced SBP, DBP, TG, VLDL, and uric acid. The protocol was registered at ClinicalTrials.gov with the identifier NCT06061926. Full article